-- Matthias Bodenstedt, Chief Financial Officer, on April 09, 2026, sold 87,795 shares in Moonlake Immunotherapeutics (MLTX) for $1,663,935. Following the Form 4 filing with the SEC, Bodenstedt has control over a total of 1,188,510 Class A ordinary shares of the company, with 1,188,510 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1821586/000121390026042629/xslF345X05/ownership.xml